Mbx Biosciences, Common Stock Total Debt
| MBX Stock | 18.50 1.99 12.05% |
MBX Biosciences, Common fundamentals help investors to digest information that contributes to MBX Biosciences,'s financial success or failures. It also enables traders to predict the movement of MBX Stock. The fundamental analysis module provides a way to measure MBX Biosciences,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to MBX Biosciences, stock.
MBX |
MBX Biosciences, Common Company Total Debt Analysis
MBX Biosciences,'s Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current MBX Biosciences, Total Debt | 156.65 M |
Most of MBX Biosciences,'s fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, MBX Biosciences, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
MBX Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for MBX Biosciences, is extremely important. It helps to project a fair market value of MBX Stock properly, considering its historical fundamentals such as Total Debt. Since MBX Biosciences,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of MBX Biosciences,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of MBX Biosciences,'s interrelated accounts and indicators.
Click cells to compare fundamentals
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, MBX Biosciences, Common has a Total Debt of 156.65 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The total debt for all United States stocks is notably lower than that of the firm.
MBX Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MBX Biosciences,'s direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of MBX Biosciences, could also be used in its relative valuation, which is a method of valuing MBX Biosciences, by comparing valuation metrics of similar companies.MBX Biosciences, is currently under evaluation in total debt category among its peers.
MBX Fundamentals
| Current Valuation | 613.91 M | ||||
| Shares Outstanding | 31.85 M | ||||
| Shares Owned By Insiders | 3.08 % | ||||
| Shares Owned By Institutions | 54.94 % | ||||
| Number Of Shares Shorted | 350.72 K | ||||
| EBITDA | (50.72 M) | ||||
| Total Debt | 156.65 M | ||||
| Book Value Per Share | (6.18) X | ||||
| Earnings Per Share | (1.48) X | ||||
| Number Of Employees | 38 | ||||
| Market Capitalization | 676.25 M | ||||
| Total Asset | 84.18 M | ||||
| Retained Earnings | (75.58 M) | ||||
| Working Capital | 79.54 M | ||||
| Net Asset | 84.18 M |
About MBX Biosciences, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MBX Biosciences, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MBX Biosciences, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MBX Biosciences, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for MBX Stock Analysis
When running MBX Biosciences,'s price analysis, check to measure MBX Biosciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MBX Biosciences, is operating at the current time. Most of MBX Biosciences,'s value examination focuses on studying past and present price action to predict the probability of MBX Biosciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MBX Biosciences,'s price. Additionally, you may evaluate how the addition of MBX Biosciences, to your portfolios can decrease your overall portfolio volatility.